DTx West Agenda

Click through the tabs below and check out the session’s lined up for DTx West 2022

Download the Agenda
  • Day 1 - Wednesday, February 23rd
  • Day 2 - Thursday, February 24th
  • Day 3 - Friday, February 25th
Day 1 - Wednesday, February 23rd
8:00am PST

Registration & Networking | Conference Platform Opens

9:00am PST

Chairs Opening Remarks and Setting the Scene

Acacia Parks, Chief Science Officer, Happify Health

9:10am PST

Keynote Presentation: Utilizing Digital Therapeutics Within the VA

David Shulkin, Former Ninth Secretary, U.S. Department of Veterans Affairs

9:35am PST

Keynote Panel Discussion: How can Obtaining Federal Contracts Can be the Golden Ticket for Digital Therapeutics Success? 

After developing clinically effective digital therapeutics, entering the market and achieving ROI is one of the greatest challenges faced by the industry. Securing a partnership with a large federal payor can be the ticket to reliable reimbursement. This session will dive into the intricacies of securing federal contracts and getting your digital therapeutic into the hands of a large pool of potential users.

  • Hear from those who have secured partnerships with large federal payers and the intricacies of building out these partnerships
  • What opportunities can partnering with federal payers provide digital therapeutics companies?
  • How can digital therapeutics companies begin their conversations with federal payers and what evidence is required?

Debra Reisenthel, Founding CEO, Freespira
David Shulkin, Former Ninth Secretary, U.S. Department of Veteran Affairs
Joe Perekupka, Chief Commercial Officer, EVERSANA

10:15am PST

Morning Refreshments & Networking

10:55am PST

Fireside Chat: A Pear Therapeutics Case Study – Achieving a Public Exit Through a SPAC Merger

As the digital therapeutics industry matures, we have been witness to a number of mergers, acquisitions and exits across the space. However, more than 80% of companies that achieved a public exit did it through a SPAC merger. This session, led by leading companies who have achieved just that, will deep dive into the ‘how’s, why’s and what’s next’ in becoming a publicly traded digital therapeutics company.

Julia Strandberg, Chief Commercial Officer, Pear Therapeutics
Charlie Steel, Chief Financial Officer, Babylon

11:35am PST

Presentation: An Insight into a Corporate VC Funds Approach at Investing and Partnering within the Digital Therapeutics Industry

  • Planting seeds and building the portfolio
  • Building momentum and engaging the corporate parent
  • Acting as a bridge between corporate parent and startups

Lana Ghanem, Managing Director, Hikma Ventures

12:00pm PST

Panel Discussion: What is the True Value within Digital Health?

In the first half of 2021  $14.7 Billion was raised by Digital Health startups, surpassing the total funding raised in 2020 within the industry. With such a massive injection of capital, digital therapeutics have the opportunity to accelerate their growth and truly establish themselves within healthcare. This panel, led by experts in the field, will dive into the intricacies of raising capital and the potential implications of injecting such huge capital into the space.

  • Why have we seen such an influx in funding and value within the digital therapeutics industry in 2021?
  • Is this influx a natural progression or has the global pandemic catalyzed the value of the industry?
  • What are the opportunities for digital therapeutics companies that come with this injection of value into the industry?
  • What are the potential implications for this rapid increase of value into the industry?
  • What steps can the industry take to ensure it continues on this upward trajectory?
  • What is the role of corporate venture capital vs institutional VCs?
  • An insight into funding and building the next generation of digital therapeutics companies

David Stevenson, Managing Director, Merck Global Health Innovation Fund
Santosh Shanbhag, Chief Financial Officer, Akili Interactive
Randall Stanicky, Chief Financial Officer, Click Therapeutics
Cris De Luca, Global Head, Digital Investments, Sanofi Ventures
Bilal Khan, Chief Financial Officer, Happify Health

12:40pm PST

Lunch and Networking

2:00pm PST

Panel Discussion: Exploring the Mutually Beneficial Relationship Between Digital Therapeutics and Employers

The integration of digital therapeutics into the employer landscape has seen success over recent years. With the adoption of digital health tools, employees are able to stay healthy while also being productive at work. This, of course, leads to increased happiness, productivity and less time out of the office while also allowing for a reliable revenue stream for the DTx partner. This panel, led by experienced leaders in the space, will dive into why the DTx and employer partnership could be a match made in heaven.

  • Are large employers exploring digital health tools for employee benefits and total rewards?
  • How can digital therapeutics integrate into employee benefits?
  • Are large employer partnerships a reliable reimbursement pathway for digital therapeutics companies?
  • How can DTx companies begin the conversation with large employers?
  • Will digital therapeutics be a mainstay in the future of employee benefits?

Jennifer Paisley, VP, Total Rewards & HR Operations, Valmont Industries

More Speakers to be Announced

2:40pm PST

Presentation: The Intersection between Pharma and Digital Therapeutics – Industry Insights from Both Sides

Digital therapeutics companies are flexible, fast-moving and have seen growth at an exponential level. Pharmaceutical companies, on the other hand, traditionally work at a slower rate and are slower to adopt new changes within healthcare. In an industry where partnerships have both blossomed and cracked apart, this session, led by an expert who has worked in both industries, will explore the differences, similarities and key takeaways on how best to work successfully  with each other.

  • What are the similarities and differences between digital therapeutics companies in the digital health field?
  • Can we identify some of the friction points in the intrinsic processes between digital therapeutics companies and pharma companies?
  • How can DTx companies and Pharma best work together to compliment the strengths of each stakeholder for a mutually beneficial partnership?

Meghan Rivera, Chief Marketing Officer & Head of Commercial, Akili Interactive
Melinda Decker, Chief Commercial Officer, Mymee

3:10pm PST

Panel Discussion: What does ‘Digital’ mean to Pharma?

Over recent years, we’ve seen the pharmaceutical industry become more involved with digital healthcare through external partnerships and internal efforts. However, the exact role of digital changes from company to company. This panel, led by the experts of digital within pharma, will explore exactly what digital means to them and their respective organisations.

  • What does digital mean to your respective pharmaceutical company?
  • How does digital health align with pharma’s traditional therapeutics approach?
  • What are pharma’s preferences in their digital health efforts? Partnering, in-house development or both?
  • Is digital a part of the mainstream efforts of the pharmaceutical industry? If not, when will this be the case?

Dennis Urbaniak, EVP, Digital Therapeutics, Orexo AB
Josh Raysman, VP, Digital Innovation Lab, Pfizer
Francesca Wuttke, Chief Digital Officer, Almirall

3:50pm PST

Afternoon Refreshments & Networking

4:30pm PST

Panel Discussion: Defining the Standards for Payer Evaluation of DTx

Digital therapeutics have demonstrated both clinical and economic value within healthcare. However, the uptake of digital therapeutics by payers has been slow and ongoing. This panel, led by a mix of innovative payers and leading DTx companies, will outline how standardising payer evaluation of digital therapeutics could lead to increased payer adoption, reliable DTx reimbursement and accelerated adoption by patients.

  • What are payers looking for when assessing coverage for a digital therapeutic?
  • Is there a standard for payer evaluation of digital therapeutics?
  • How can we streamline the process of connecting payers and DTx companies for increased and improved coverage?
  • Is value-based contracting the best path forward for DTx & payer partnerships?
  • Is it possible to set a defined process for digital therapeutics companies to get in front of payers?

Corrado Panno, VP, Business Development, Magellan Health
Theresa Juday, Director, Speciality Product, CVS Caremark
Katya Siddall, VP, Product Development & Innovation, Blue Cross and Blue Shield of Kansas City

5:10pm PST

Chairs Closing Remarks

Acacia Parks, Chief Science Officer, Happify Health

5:15pm PST

End of DTx West Day 1

Download Agenda
Day 2 - Thursday, February 24th
8:00am PST

Registration & Networking | Conference Platform Opens

9:00am PST

Chairs Opening Remarks and Setting the Scene

Abhishek Shah, Co-Founder & CEO, Wellthy Therapeutics

9:10am PST

Keynote Presentation: An Insight into the Mind of a Digital Therapeutics Prescriber

Although established across numerous healthcare systems within and outside of the US, the uptake of digital therapeutics by providers has been a slow process. This session, led by real prescribers of digital therapeutics, will dive into the intricacies of provider adoption and the process of implementing digital therapeutics into a patients healthcare journey.

Audrey Kern, Global Medical Director, Pear Therapeutics

9:35am PST

Panel Discussion: How can we Successfully Scale Digital Therapeutics for Health Equity and Inclusion across Economical, Cultural and Locational Boundaries?

Digital therapeutics have proven to improve patient accessibility, adoption and engagement while still delivering high quality clinical care and providing economical benefits. However, key challenges remain to ensure full integration into healthcare and ensuring health equity. The panel will explore exactly how digital therapeutics can deliver high-quality healthcare to all.

  • Is the current healthcare system delivering high-quality healthcare to the entire population?
  • What are the social determinants that limit access to healthcare in the current climate?
  • How does digital health and digital therapeutics lend itself to improved healthcare equity?
  • How can robust personalized data generated by digital therapeutics help providers improve quality of care?
  • As an industry, how can we ensure the healthcare system continues to improve for all patients, regardless of social determinants?

invited Speakers
Karen DeSalvo, Chief Health Officer, Google
J. Nwando Olayiwola, Chief Head Equity Officer & Senior Vice President, Humana

10:15am PST

Morning Refreshments & Networking

10:55am PST

Panel Discussion: How can Digital Therapeutics Companies & Providers Groups Collaborate for Greater Efficiency and Transparency?

Although we’ve seen some success in the market for digital therapeutics, uptake by providers has been off to a slow start. However, over recent years we’ve seen more innovation provider groups utilize these new therapeutic approaches with success. This session, led by frontline healthcare providers and digital therapeutic companies, will explore how the integration of digital therapeutics into the healthcare system can lead to both higher quality of care and improve clinical success.

Santosh Mohan, VP, Digital, Moffitt Cancer Center
Leanne Mauriello, Director, Lifestyle Medicine, Spectrum Health
Francisco Rhein, System VP, IT Innovation & Digital Care Transformation, CommonSpirit Health
Ema Offidani, Head of Medical Affairs, Click Therapeutics

11:35am PST

Presentation: Providing the Industry with an Update on the Clinical Landscape within Digital Therapeutics

  • An in-depth look as to if there is a defined bar of validation set for digital therapeutic clinical trials
  • Do FDA and non-FDA regulated Digital therapeutics require different levels of validation or should it be uniform?
  • A look at the current requirements for DTx clinical trials to be considered successful.

Gina Kackloudis, Director of Clinical Operations, Happify Health

12:00pm PST

Lunch and Networking

1:30pm PST

Presentation: How Big Health are Tackling Wider Mental Health Issues by Addressing Sleep

  • An insight into the recent study looking into the prevalence of mental health and insomnia across multiple populations
  • What is the impact of under-served populations on mental health?
  • How are Big Health addressing wider mental health issues starting with sleep as a starting point?

Colin Espie, Co-Founder & Chief Scientist, Big Health

2:05pm PST

Panel Discussion: Tackling the Operation Challenges of Integrating Digital Therapeutics into the Healthcare System

The digital therapeutics industry has successfully navigated developing clinically effective digital solutions that are, in many cases, seen to rival that of traditional therapeutics. However, an often overlooked challenge is the operational aspects of having your digital solution in the market. This panel, led by those who have successfully implemented digital tools into the hands of the patients, will dive into the operations and infrastructure required to support a digital therapeutic in the market.

Speaker to be Announced

2:45pm PST

Afternoon Refreshments & Networking

3:25pm PST

Presentation: Incorporating Disparate Feedback (UX, SME, Clinical Outcomes & Analytics) Into Product Development

Jessica Lake, Chief Science Officer, Limbix

3:50pm PST

Presentation: Building a Digital Therapeutics Product in a Regulated Environment

The digital therapeutics industry is packed with novel and innovative digital solutions for numerous disease states. However, not all digital therapeutics are built the same. This session, led by the experts in product development, will dive into the intricacies of building a digital health solution while holding ourselves accountable to the clinical, product and design boundaries while also building the foundations for creating health equity.

  • What are the key lessons learned of building a digital therapeutics product within a regulated environment?
  • How can digital therapeutics companies hold themselves accountable within the clinical, product and design boundaries of the industry?
  • How can digital therapeutics companies create the foundations to ensure health equity within the industry?
  • An insight into the importance of basing digital therapeutic development for widespread inclusion across social determinants

Venkat Rao, Director of product Development, Big Health

4:30pm PST

Chairs Closing Remarks

Abhishek Shah, Co-Founder & CEO, Wellthy Therapeutics

4:40pm PST

End of DTx West Day 2

Download Agenda
Day 3 - Friday, February 25th
8:00am PST

Registration & Networking | Conference Platform Opens

9:00am PST

Chairs Opening Remarks and Setting the Scene

Abhishek Shah, Co-Founder & CEO, Wellthy Therapeutics

9:15am PST

Presentation: Utilizing Digital Health to Manage Chronic Heart Conditions

Representative from Hello Heart

9:45am PST

Presentation: Case Study Presentation by S-Alpha Therapeutics

  • A first-look at S-Alpha Therapeutics Clinical Data
  • An insight into S-Alpha Therapeutics approach at developing digital solutions for multiple disease areas
  • What’s next for S-Alpha Therapeutics?

SeungEun Choi, Chief Executive Officer, S-Alpha Therapeutics

10:15am PST

Presentation: 5 Ways We’ve Conquered our Fear of Being Truly Patient Centric

Most digital health companies have the good intention of being human centric whilst oftentimes ignoring the human context behind restrictive medical models. This can be boiled down to being fearful of radical truth from patients and having to face the reality that their product might not produce the desired outcomes on both the human experience and medical side. This showcase will highlight what we’ve learned on our successful journey to co-build the Quin app with hundreds of people with diabetes still involved in our daily operations.

  • How has Quin enabled true patient centricity when developing and offering the digital health solution to diabetes patients?
  • How can digital therapeutics companies include patients early on in their developmental journey?
  • How are Quin continuing to include patients as they grow and scale their digital therapeutic?

Cyndi Williams, Founder & CEO, Quin

10:45am PST

Morning Refreshments & Networking

11:15am PST

Panel Discussion: Where does Innovation need to Occur Within the Industry to Continue Advancing Digital Therapeutics?

Speakers to be Announced

11:55am PST

Chairs Closing Remarks

Abhishek Shah, Co-Founder & CEO, Wellthy Therapeutics

12:00pm PST

Close of DTx West 2022

Download Agenda